Nanoscale Enzyme Therapy - News Item

Nov 27 2003

An Israeli subsidiary to BioDelivery Sciences International Inc. (BDSI) is being created to develop nanoscale drug-delivery therapies to treat an inherited disease caused by an enzyme deficiency. Tentatively called Biorazyme Ltd., the company is co-owned by Newark, N.J. based BDSI and Israeli joint venture partners. It will develop a new oral enzyme replacement for Gaucher Disease.

BDSI's Bioral delivery technology uses nanocrystalline delivery vehicles made from all-natural components that wrap around the enzyme and allow it to be delivered into the body. 

Posted 25th November 2003

Tell Us What You Think

Do you have a review, update or anything you would like to add to this article?

Leave your feedback
(Logout)
Your comment type
Submit

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback